Tuesday, June 23, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jun 22, 2026
In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy
background ▾
- •FDA has fundamentally shifted its stance on rare disease gene therapy approvals, abandoning requirements for untreated control arms and larger patient populations in favor of accelerated pathways using natural history data—a major policy reversal signaling new leadership's commitment to expedited access
- •The FDA's reversal on the heparan sulfate biomarker, previously deemed insufficient, appears driven by its own approval of Denali's Avlayah using the same biomarker and intense rare disease advocacy pressure, creating regulatory precedent inconsistency that undermines scientific rigor
- •Watch for Regenxbio's resubmission timing and outcome as a bellwether for FDA gene therapy approval standards; monitor whether Denali's Avlayah post-marketing data impacts the agency's long-term validation of this biomarker approach and sets precedent for other rare disease candidates
RegenxbioFDADenali TherapeuticsNavsunli (clemidsogene lanparvovec)AvlayahAMT-130
→ Read original articlePolicy•KFF•Jun 23, 2026
Is AI (Still) Biased?
background ▾
- •AI bias in clinical algorithms persists as a critical healthcare issue; Obermeyer's prior research revealed a widely-used algorithm systematically underestimated Black patients' health needs, influencing hospital practices globally
- •Data context and provenance—not just algorithmic precision—are the primary determinants of AI fairness and clinical utility in patient management
Policy•Fierce Biotech•Jun 22, 2026
Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months
background ▾
- •HHS-wide initiative targets 6-12 month reduction in Phase 1 timelines through expedited IND program, updated CMC guidance, and shift away from animal models for preclinical testing
- •FDA and NIH are establishing new infrastructure (website, call center, clinical trial network) to support trial sponsors, particularly small companies navigating early-stage development
- •Success depends on sustained agency coordination, sponsor adoption, and whether streamlined pathways maintain adequate safety standards without increasing trial failures downstream
Policy•STAT News•Jun 23, 2026
Opinion: Ending birthright citizenship could be a public health disaster
background ▾
- •Nearly 9% of U.S. births annually could be denied birth certificates and public health insurance eligibility (Medicaid/CHIP) if birthright citizenship is eliminated, directly threatening preventive and acute care access for hundreds of thousands of children born to immigrant parents
- •The policy would expand migration-related adverse childhood experiences (ACEs)—including chronic deportation fear, parental separation, and detention exposure—to millions of U.S.-born children, with documented long-term negative health impacts
- •State maternal health coverage mechanisms (FCEP and Medicaid Expansion coverage for pregnant immigrants) would face significant disruption, potentially reducing prenatal care access and birth outcomes in vulnerable populations
Policy•STAT News•Jun 22, 2026
Trump administration targets disability integration mandate in DOJ memo
background ▾
- •DOJ memo signals Trump administration intends to deprioritize enforcement of the Olmstead integration mandate, which has been settled law for 25+ years, despite acknowledging community care is cheaper and more aligned with established federal policy.
- •The memo may presage legal challenges to the Olmstead precedent itself, and is expected to result in DOJ withdrawal from its historical role as enforcer of disability integration rights.
- •Watch for: actual litigation testing the memo's arguments; state Medicaid decisions that reduce home and community-based services; and whether disability advocacy groups file preemptive lawsuits to defend integration protections.
Market Access
Market Access•Fierce Biotech•Jun 22, 2026
Sanofi, Pangaea ink AI partnership deal to detect underdiagnosed genetic disease
background ▾
- •Sanofi is using AI-powered clinical decision support to address diagnostic underrecognition of AATD, where 90% of patients go undiagnosed despite existing clinical data in their records
- •The platform integrates with existing EHR systems without operational burden, enabling real-time patient identification and flagging for clinician review
SanofiPangaea DataAlpha-1 Antitrypsin
→ Read original articleMarket Access•Endpoints News•Jun 22, 2026
After 'redesign,' WuXi Biologics sets new timeline for Massachusetts factory completion
background ▾
- •WuXi Biologics' Massachusetts biomanufacturing facility completion pushed to 2028, approximately a decade after initial announcement
- •Facility redesign suggests potential technical, regulatory, or operational challenges in the original plan
WuXi Biologics
→ Read original articleMarket Access•Endpoints News•Jun 22, 2026
Lilly allies with BioArctic; Antengene and Insilico sign deals
background ▾
- •Eli Lilly has partnered with BioArctic, signaling continued M&A and partnership activity in biotech despite market conditions
Eli LillyBioArcticAntengene
→ Read original articleMarket Access•Fierce Biotech•Jun 22, 2026
For biopharma manufacturing at speed and scale, the future is flexible
background ▾
- •CDMOs are increasingly differentiated by manufacturing flexibility—single-use equipment, modular facilities, and agile teams—rather than fixed dedicated suites, to accommodate sponsor timeline pressures and shifting priorities across diverse modalities.
Resilience
→ Read original articleMarket Access•Endpoints News•Jun 22, 2026
AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
background ▾
- •AbbVie's $10.9B acquisition of Apogee is the company's largest M&A transaction since the Allergan deal, signaling aggressive portfolio expansion in immunology
- •Zumilokibart (long-acting IL-13 inhibitor) represents a differentiated mechanism with potential applications across dermatology, allergy, and systemic immune conditions
- •Monitor Phase 2/3 clinical data readouts for zumilokibart and Apogee's pipeline to assess whether this premium valuation delivers competitive advantages in crowded immune-mediated disease markets
AbbVieApogee Therapeuticszumilokibart
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 22, 2026
Exelixis’ Cabometyx successor fails primary endpoint in colorectal cancer trial amid FDA review
background ▾
- •Zanzalintinib missed statistical significance on the NLM subgroup primary endpoint (17% vs. expected 23% OS benefit), a critical metric that CEO Morrissey acknowledged was important 'from a marketing point of view'
- •The drug met its dual primary endpoint requirement by succeeding on OS in the overall population (20% improvement), supporting potential FDA approval despite endpoint failure
- •Exelixis changed the trial's primary endpoints twice (2022→2024→2025), mirroring Merck/Eisai's Leap-17 strategy pivot and creating potential FDA regulatory scrutiny over post-hoc subgroup optimization
ExelixisRocheBayerzanzalintinibTecentriqatezolizumab
→ Read original articleClinical Trials•Fierce Biotech•Jun 22, 2026
Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis
background ▾
- •Tulisokibart achieved the primary endpoint of clinical remission in the ATLAS-UC Phase 3 induction study—first anti-TL1A antibody success on this endpoint in UC—validating Merck's $11 billion Prometheus acquisition strategy
- •Merck faces significant competitive hurdles from entrenched IL-23 and JAK inhibitor classes; analysts expect tulisokibart will underperform unless it demonstrates superiority on maintenance, endoscopic, histologic, or biomarker measures
- •This trial success is part of Merck's broader pipeline repositioning ahead of Keytruda patent cliff (late decade); investors and analysts awaiting additional late-stage validation from other recent acquisitions (Verona, Cidara, Terns) before reassessing Merck's post-LOE prospects
MerckPrometheus BiosciencesTakedatulisokibartEntyvioSkyrizi
→ Read original articleClinical Trials•Endpoints News•Jun 23, 2026
Flagship's Abiologics uses AI to build mirror-image proteins for new drugs
background ▾
- •Abiologics has developed an AI platform to design D-amino acid mirror-image proteins, potentially offering enhanced pharmacokinetic properties over standard protein therapeutics
- •This is a technology proof-of-concept at the preclinical stage; no clinical trial data, regulatory filings, or partnered programs are mentioned
AbiologicsFlagship Pioneering
→ Read original articleClinical Trials•Endpoints News•Jun 22, 2026
MapLight to discuss autism drug's future with FDA after Phase 2 miss
background ▾
- •MapLight's autism drug failed its Phase 2 trial, missing primary efficacy endpoints
- •The company is pursuing FDA discussions to determine viability of continuing development despite the negative data
- •Monitor for FDA meeting outcomes and any potential protocol modifications or decision to advance/discontinue the program
MapLight Therapeutics
→ Read original articleClinical Trials•Endpoints News•Jun 22, 2026
Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win
background ▾
- •Prometheus' lead IBD program achieves Phase 3 success, the first major clinical validation of Merck's $10.8B acquisition strategy
- •Positive readout reduces development risk for a cornerstone asset in Merck's gastroenterology strategy and validates the acquisition premium paid in 2023
- •Monitor upcoming regulatory submissions and competitive efficacy comparisons against established IBD treatments and other pipeline programs
MerckPrometheus Biosciences
→ Read original article